Solingen Private Equity

The two directors named on the firm's website, Paul Betts and Robin Womersley, lead investment decisions. The firm operates as an investor group rather than through a large committee structure. Both bring operator experience to the process, consistent with the firm's positioning as entrepreneurial investors.

Solingen publicly states a minimum profit threshold of £500,000 for potential UK portfolio companies. This floor signals a focus on established, cash-generating small-to-mid-size enterprises rather than early-stage or turnaround situations. The requirement also aligns the firm with management teams looking for a partner that understands operational maturity.

Solingen's core market is the United Kingdom, with a heavy concentration in the North of England. Its portfolio does include one business, Burgess Diagnostics, which operates a network of veterinary imaging sites across both the UK and Ireland. In practice, this means the firm will back UK-headquartered companies that may serve cross-border markets, but it does not run a pan-European or global direct-investment strategy.

The firm's operator DNA shapes its origination strategy. As a private investor group led by directors with experience running businesses, Solingen relies on entrepreneurial networks and direct relationships rather than broad auction processes. Its completed deals — including the management buyout of Academic Appointments and the retirement-sale acquisition of Gem Scientific — suggest a pattern of sourcing proprietary or limited-auction opportunities from founders and incumbent management teams.

Yes. Solingen maintains an active investment posture and continues to present its full portfolio on its website, with its most recently dated investment being Washstation in June 2019. The firm has not publicly announced fund closures or a pause in deployment, indicating it remains open to new profitable UK SME opportunities that meet its £500,000 profit minimum.